Azathioprine treatment in multiple sclerosis; Pretreatment assessment of metaboliser status [4]

Journal of Neurology Neurosurgery and Psychiatry

Volumn 70, Issue 6, 2001, Pages 815-

  Thomas, F J ^a   Hughes, T A T ^a   Anstey, A ^a  

^a UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; MERCAPTOPURINE; TRANSFERASE; XANTHINE OXIDASE;

BLOOD SAMPLING; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; DRUG EFFECT; DRUG INDICATION; DRUG METABOLISM; DRUG OXIDATION; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME ACTIVITY; GENETIC POLYMORPHISM; HUMAN; LETTER; METHYLATION; MULTIPLE SCLEROSIS; PATIENT SELECTION; PRIORITY JOURNAL; TREATMENT PLANNING;

AZATHIOPRINE; HUMANS; MULTIPLE SCLEROSIS;

EID: 0034990079     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.70.6.815     Document Type: Letter

References (5)

1. New treatments and azathioprine in multiple sclerosis
2. Pancytopenia related to azathioprine: An enzyme deficiency caused by a common genetic polymorphism; A review
3. Mercaptopurine pharmacogenetics: Monogenetic inheritance of eryrthrocyte thiopurine methyl transferase activity
4. Pharmacogenetics of acute azathioprine toxicity: Relationship to thiopurine methyl transferase genetic polymorphism
5. Overview of azathioprine treatment in multiple sclerosis